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Abstract
Interferon alpha linked to apolipoprotein A-I has been recently proposed as an improved interferon-based therapy. In the
present study, we aimed to develop a computational model to gain further insight into the in vivo behaviour of this new
fusion protein. In order to facilitate in vivo evaluation of interferon and the fusion protein without altering their biological
properties, green fluorescent protein was incorporated into their structures. Kinetic and dynamic behaviour of both
compounds was successfully described after plasmid hydrodynamic administration and in situ synthesis of the studied
proteins. Results from the modelling exercise showed that apolipoprotein A-I conferred a modified kinetic behaviour,
varying molecule distribution and prolonging half-life without altering liver dynamic performance. However, differences in
the gene expression activity were observed at brain level between both compounds. Those differences could be explained
by modifications in the dynamic, but also in the biodistribution properties, which would be worth evaluating in future
experiments. Therefore, the modelling approach provided a global comprehension of a complex system and allowed us to
compare the in vivo behaviour of both compounds and to identify critical aspects that might be important to understand
the system better and suggests a need for new model-based experiments.
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Introduction
Interferons (IFN) are a family of cytokines widely used in clinics
owing to their antiproliferative, antiviral and immunomodulatory
properties [1,2]. IFNa was first proved to be beneficial in the
treatment of hepatitis C in 1986 [3], and, although the rate of
success in monotherapy was low (12–16%), the addition of the
antiviral agent ribavirin significantly enhanced the therapeutic
response (35–40%) [4]. Further improvements were achieved
when pegylated interferons were put on the market. These new
molecules showed a better kinetic profile and an increased rate of
therapeutic response, and thus became, in combination with
ribavirin, the standardized regime used in clinical medicine for
chronic hepatitis C [5,6]. Nevertheless, the rate of sustained viral
response in chronic patients is still insufficient (54–56%) [7,8] and
the severity of some side effects, such as neutropenia, thrombo-
cytopenia [9,10] and specially psychiatric disorders like depression,
greatly limit their use in clinical practice [10,11], being necessary
to discover new therapeutic agents.
Different strategies have been proposed to improve interferon-
based therapies (reviewed in [12]). One molecule recently
developed is a potent immunostimulatory fusion protein, termed
IA, obtained when IFNa is covalently attached to apolipoprotein
A-I (ApoAI) [13], major component of high-density lipoproteins
(HDLs) [14]. The presence of ApoAI in this new molecule has
proven not only to facilitate the incorporation of both entities into
the circulating HDLs, which translates into increased stability and
prolonged half-life of IA, but also to provide a different in vivo
biodistribution profile, with promising liver-targeting qualities
[15–17].
HDL uptake in the brain is a highly regulated process [18], and
facilitated transfer through the blood-brain barrier (BBB) has been
previously described for molecules bound to ApoAI [19]. The
different brain distribution between IFNa, which is thought to
enter into the brain through passive diffusion [20,21], and IA,
could be expected to translate into limited IA brain entry, and
therefore central nervous system-related side effects, at high doses
like those used in clinical practice.
Kinetic/dynamic modelling has proven to be an interesting
approach to describe and understand the in vivo behaviour of
therapeutic molecules, providing a useful tool to explore different
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mechanisms of action, new scenarios and to optimize experimental
designs in silico [22–24]. A few examples where a modelling
approach has been followed to evaluate the kinetic of different
non-viral or viral vectors in order to improve their in vivo
behaviour [25,26], or to study the dynamic (efficiency) of vectors
[27,28], can be found in the literature. However and despite its
advantages, its use in the gene therapy field is still limited [29],
especially due to the amount of experimental data and compu-
tational resources needed, and our knowledge non-integrated
kinetic/dynamic model has been develop so far in preclinical
settings.
The final aim of the study is to evaluate the kinetic and dynamic
properties conferred by the incorporation of ApoAI to therapeutic
molecules such as IFNa through mathematical modelling.
Nevertheless, model-based is a quantitative approach, and
techniques to quantify IFNa might not be sensitive enough or
might provide an unacceptable background due to detection of
endogenous protein. Therefore, in order to facilitate the quanti-
fication of this protein in vivo, green fluorescent protein (GFP)
sequence was added to the plasmid codifying for the IA protein.
GFP is a fluorescent protein widely used in molecular biology.
Among the known properties, we can highlight its great versatility
and its ability to preserve the native function of proteins after their
fusion to both the C and N-terminal region of GFP [30].
Accordingly, the IA codifying plasmid with the GFP sequence in
between (IFNGFPApo), and the interferon-GFP plasmid
(IFNGFP) or the apolipoprotein AI fused to GFP (GFPApo) as
comparison molecules, were cloned in order to evaluate the
differential properties conferred by ApoAI.
Here, we demonstrate how a computational semi-mechanistic
model can be used to quantitatively characterize the kinetic and
dynamic properties of IFNGFPApo and IFNGFP, showing a
modified kinetic profile for both molecules without modifying
IFNa efficacy in liver. However, dynamic differences between
these two compounds were found in brain, suggesting the need
for new experiments to clarify the behaviour of the system at
this level.
Results
Evaluation of pGFPApo, pIFNGFP and pIFNGFPApo
GFP molecule was selected for this project due to its known
capacity to bind molecules to both GFP terminal regions of the
protein without modifying the structure of any of the compounds
implied, and therefore conserving their native properties. Never-
theless, GFP fluorescence, antiviral IFNa activity and the capacity
of ApoAI to be transported inside the HDLs were evaluated to
confirm whether the biological properties of each of the three
proteins were retained.
To assess the bioavailability of GFP, 293T cells were
transfected with pGFPApo, pIFNGFPApo or pIFNGFP, and
observed through fluorescence microscopy after 24 h of
incubation (Fig. 1A). Green fluorescence was detected in all
scenarios, although different distribution patterns could be
observed. While IFNGFP was homogeneously distributed inside
the cell, GFP bound to IA presented a heterogeneous
distribution with apparent fluorescence accumulation around
the cytoplasmatic cell borders, like those observed in GFPApo.
To gain further insight into the differential distribution,
transfected cells were stained with a red-fluorescent dye to
visualize the Golgi apparatus and analyzed by confocal
microscopy (Fig. 1B). IFNGFPApo also presented an interme-
diate distribution pattern between GFPApo, only detected in the
Golgi and absent from the nucleus, and IFNGFP, homo-
genously located in both nucleus and Golgi.
Supernatants obtained after 293T cell transfection were used to
evaluate the capacity of the three synthesized proteins to protect
L929 cells against encephalomyocarditis virus infection. As
expected, only those molecules where IFNa was present in the
structure were able to protect L929 cells against the viral infection
and subsequent cell death (Fig. 2A). Moreover, both, IFNGFP
and IFNGFPApo presented a similar value of drug concentration
needed to inhibit 50% of cellular death (IC50) (p.0.05) (Log IC50
equal to 3.32 and 3.59 respectively).
Regarding the preservation of the native ApoAI function,
20 mg of either pIFNGFP or pIFNGFPApo were administered
to the BALB/c mice strain (n = 3 mice per group) through
hydrodynamic injection. 24 hours later, blood samples were
obtained, the different plasma lipoprotein fractions were
separated until the last fraction was considered to be free of
lipoproteins (LDP, lipoprotein-depleted plasma) and IFNa
content was measured in each of the fractions. In the case of
pIFNGFP, IFNa presence was only detected in the LDP
fraction (Fig. 2B), and not in the very low density lipoprotein
(VLDL), low density lipoprotein (LDL), or high density
lipoprotein (HDL) fractions. Hence, we concluded that IFNGFP
was not able to bind to the plasma lipoproteins. Only when
ApoAI was present in the structure was IFNa also detected in
the HDLs fraction (Fig. 2B). To ensure that solely IFNGFPApo
was able to travel along with HDLs, western blotting against
ApoAI over the HDL fraction of both molecules was performed.
A band around 31 kDa corresponding to endogenous ApoAI
could be observed in both fractions, yet only the IFNGFPApo
fraction presented a higher band (around 71 kDa) representing
the triple fusion protein bound to HDL (Fig. 2C).
In conclusion, three plasmids codifying for three novel fusion
proteins were obtained without altering the three-dimensional
structure of any of the molecule components, and consequently,
retaining the antiviral activity of IFNa (therapeutic drug), the
capacity of ApoAI molecule to travel along with the HDLs and the
GFP structure introduced to increase the sensibility and specificity
of the quantification method. Therefore, IFNGFP and IFNGF-
PApo plasmids could be used to evaluate in vivo the kinetic and
dynamic differences between the main molecules of interest: IFNa
and IA.
Kinetic Model
In vivo performance of IFNGFP and IFNGFPApo was
evaluated, focusing especially on hepatic production, serum
profiles, and brain distribution. The model was developed
following a step-wise approach, where mRNA levels and liver (l),
serum (s) and brain (br) protein measurements were added
sequentially to the model.
The five panels in Figure 3 show that the final model
represented schematically in Figure 4 and mathematically by the
set of equations 1–11 captured well the concentration versus (vs)
time profiles in liver, serum, and brain of mRNA, IFNGFP, and
IFNGFPApo. Kinetic parameters are summarized in Table 1.
Precision of model parameters, computed as the ratio between the
standard errors (listed in Table 1 in parenthesis) and the estimate
of the parameters were in general below 50% indicating that
model parameters were indeed identifiable given the model and
the available data.
Interestingly, the kinetics of hepatic transcription from pDNA to
mRNA for the two molecules could be described with the same
model and same set of model parameters (Table 1).
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On the contrary, a poor model performance was observed when
a common model structure and parameter estimates were
attempted to describe liver and serum kinetics of both proteins
simultaneously. Therefore, each molecule was independently
analysed. IFNGFP profiles were successfully described using a
chain of three transit (signalling) compartments to delay liver
IFNGFP synthesis (dMVOF = 18 when incorporating one extra
parameter and compared with no delay, p,0.001) and reversible
mass transfer between liver and serum compartments (equations
6–7) (Fig. 3B). The same model structure, though with a different
set of parameters, was applied to the IFNGFPApo data from liver
and serum also observing an improvement in the fit when a delay
in the protein synthesis was introduced (dMVOF = 73 when
incorporating one extra parameter, p,0.001) (Fig. S1A). How-
ever, the mean transit time estimated for IFNGFPApo was
significantly different from the IFNGFP estimated one (15 h versus
2.76 h respectively) (p,0.001) suggesting a slower synthesis
process. A further improvement in the IFNGFPApo model
performance was observed when including an extra compartment
for protein distribution outside the serum (central) compartment
(dMVOF = 19 when incorporating two extra parameters p,0.01)
(Fig. S1B). During model building, degradation of both proteins
from the serum compartment was also assayed but it did not
improve model description (p.0.05).
The concentration of both proteins in the liver was similar, as
can be seen in panels 3b and 3c, but in serum, the difference in
levels was more apparent showing an increase in serum half-life
(Figure S2 allows a better comparison of the rates of elimination
from serum). Serum half-life is a parameter related to both,
elimination and disposition processes. The area under the curve
was greater for the case of sIFNGFPApo, suggesting a lower
clearance. This fact, together with the existing differences in the
distribution properties of both proteins, supported by the need of a
peripheral compartment in the IFNGFPApo case, would be
responsible for an increase in the terminal half-life in serum.
However, as that total amount of synthesized protein remains
unknown, it was not possible to calculate an apparent volume of
distribution.
Results from the brain analysis indicated a faster turnover brain
kinetics regarding IFNGFPApo. The slower first order rate
constant of exit from the brain compartment was four-fold lower
for brIFNGFP, and although it reached not statistical significance,
it pointed towards an extended distribution, as will be discussed
later in conjunction with the dynamic analysis.
Dynamic Model
Interferon-stimulated genes (ISGs) are genes selectively activat-
ed by interferon, which can therefore be used as a measure of
interferon activity. Two main organs were selected regarding their
clinical interest: liver, main target organ of the therapy, and brain,
where important and greatly limiting side effects arise with the
current standard of care. ISG15 and 29-59 OAS genes were
selected as indirect measurements of IFNa activity.
In the liver and for the two genes studied, the synthesis was best
described with a saturation (non-linear) model of the form
Figure 1. Evaluation of GFP activity by microscopy analysis. 26105cells per well were seeded and transfected with pGFPApo, pIFNGFP and
IFNGFPApo complexed in PEI 25000(kDa). 24 hours after transfection of GFPApo (left), IFNGFP (center) and IFNGFPApo (right) A. fluorescence was
evaluated by fluorescence microscopy or B. cells were dyed with BODIPY TR and analyzed by confocal microscopy.
doi:10.1371/journal.pone.0042100.g001
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kSx[IFN/(IFN+IFN50)] (AIC value equal to 217.8 and 210.7 for
OAS and ISG15 respectively) instead of the linear model kSxIFN
((AIC value equal to 230.0 and 237.0 for OAS and ISG15
respectively). For each gene, proteins profiles were successfully
described considering the same gene expression efficiency for both
compounds (Figs. 5A–B). Model performance did not signifi-
cantly improve if different sets of model parameters were estimated
(dMVOF equal to 2 and -9 points for OAS and ISG15 respectively
when incorporating two new parameters, p.0.05). Model
parameters are summarized in Table 2.
The same approach was followed to describe brain ISG
expression levels; however, it was found that expression efficiencies
differed between IFNGFP and IFNGFPApo for the two genes
(Table 2) (dMVOF equal to 15.2 and 35.1 points for OAS and
ISG15 respectively when considering two different synthesis rates,
p,0.001). Non-linear models for gene expression in brain were
also tested, but they did not improve model performance (AIC
value equal to 211.6 and 210.4 for OAS and ISG15 respectively,
but with standard errors greater than 100%) compared with the
linear approach (AIC value equal to 219.3 an 210.7 for OAS and
ISG15, respectively with proper standard errors). Results indicated
that IFNGFP induced gene expression more efficiently in a
significant manner, since brain levels were lower (Fig. 3D–E) and
gene levels very similar (Figs. 5C–D). Once the genes were
expressed in brain their degradation rate constant was the same
regardless of the type of protein (IFNGFP or IFNGFPApo)
responsible for the synthesis (dMOVF equal to 23.5 and 20.2
points for OAS and ISG15 respectively when including one model
parameter, p.0.05).
Discussion
Hepatitis C is considered a major health issue affecting about
3% of the worldwide population. Pegylated interferon in
combination with ribavirin is the current standard therapy;
however, this approach shows limited treatment efficiency
(around 50% of the patients) and major side effects, such as
haematological or neuropsychiatric alterations, and therefore
new treatment strategies are needed [5,31]. A novel fusion
protein between IFNa and apolipoprotein A-I has recently been
proposed by Fioravanti et al [13]. This new molecule has proven
not only to prolong interferon half-life, but also to decrease the
activation of interferon-stimulated genes in the brain at
therapeutic doses, indirectly suggesting a modification in the
Figure 2. Evaluation of IFNa and ApoAI biological properties. A. recombinant IFN (rIFN), GFPApo, IFNGFP and IFNGFPApo antiviral efficacy
against encephalomyocarditis virus expressed as percentage of surviving cells against molecule dilution. B. Determination by ELISA of the IFNa
content of the different plasma lipoprotein fractions obtained after 24 h of hydrodynamic injection of 20 mg IFNGFP or IFNGFP plasmid. Pooled
samples of three mice per group were used. C. Western blot against ApoAI of HDL plasma fractions obtained as previously described.
doi:10.1371/journal.pone.0042100.g002
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IFNa biodistribution profile and consequently, in its adverse
events.
To further explore the biodistribution properties of this new
entity, GFP coding nucleotides were incorporated into IA plasmid,
seeking an increase in the sensitivity and a decrease in the limit of
quantification of the method by incorporating an exogenous
compound. Green fluorescence, antiviral activity and inclusion in
the HDLs were evaluated to ensure that the cloning process had
not altered GFP, IFNa and ApoAI characteristics. All conjugates
were found to keep their native functions, and therefore
IFNGFPApo and IFNGFP, as control compound, were used to
study in vivo the biodistribution and kinetic changes produced
when ApoAI was anchored to IFNa.
Protein biosynthesis can be an expensive and long process,
sometimes unworthy in the early stages of drug development,
when the relevance of the new therapeutic protein has not yet
been clearly demonstrated. Hydrodynamic injection has been
shown to be a useful technique to evaluate these new compound
properties in vivo by administering naked plasmid, and forcing its
expression in situ [32,33].
A sequential kinetic model incorporating liver, blood and brain
compartments was developed for IFNGFPApo and for IFNGFP.
To jointly describe the mRNA kinetics of both compounds, a
model previously published [28] was implemented.
A similar simultaneous fit was also assayed for hepatic and
serum GFP concentrations, but different dynamic profiles were
observed for each compound under study, with a delay in the
hepatic and serum peak concentrations and prolonged plasma
levels of IFNGFPApo. Banerjee et al [34] studied the
biosynthesis and secretion of ApoAI, suggesting a Golgi
accumulation of the protein prior release to blood flow. These
results are in agreement with the observed IFNGFPApo
synthesis dynamics (Fig. 1B), but also with the fluorescence
accumulation detected when 293T cells were transfected with
pIFNGFPApo (Fig. 1A). From a modelling perspective, these
hypotheses are supported by the lower transit rate constant
Figure 3. Mean concentration-time profiles of mRNA and proteins in liver, serum and brain. 20 mg of either IFNGFP or IFNGFPApo
plasmids were administered by hydrodynamic injection. At the selected time points, a group of mice was sacrificed and the liver, the brain and a
serum sample were obtained to quantify levels of GFP protein or mRNA. Observed (points) and predicted levels (lines) were plotted versus time for
(A) mRNA gene expression of both molecules in liver, (B) serum and liver GFP levels after IFNGFP or (C) or IFNGFPApo plasmid administration, and (D)
brain levels reached with IFNGFP or (E) IFNGFPApo. Brain and liver levels are expressed in GFP pg/mg protein; serum levels are expressed on GFP pg/
mL units and mRNA on gene expression units in log scale.
doi:10.1371/journal.pone.0042100.g003
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estimated for IFNGFPApo than for IFNGFP and the need for a
peripheral compartment, which inclusion was only statistically
significant in the case of the IFNGFPApo compound. Hepatic
IFNGFPApo levels are controlled by the amounts present in the
last transit compartment more flattened the lower the value of
the transit rate constant (Fig. S3) and thus explaining the
Figure 4. Schematic representation of the PK/PD model. IFNGFP model is represented in black. IFNGFPApo modifications over the basic
IFNGFP model are drawn in grey. Common model process equivalences: kNUNC, first order rate constant of degradation of DNA; kINT, first order rate
constant controlling the formation and elimination of DNA’; kS1 and kS2, first order rate constants of expression of mRNA from DNA and DNA’,
respectively; kDEG, first order rate of degradation of mRNA; kTRAN, first order constant rate of transit; kS and kD, first order rate constants of synthesis
and degradation of the hepatic protein; kls and ksl first order rate constants of distribution between liver and serum compartments; ksbr, first order
rate constants of brain input; kE, first order rate of degradation of brain IFN; kS_ISG and kD_ISG, the first order process of synthesis and degradation in
liver or brain. Specific parameter of the IFNGFPApo model: ksp and kps, distribution rate constants between central serum compartment and
peripheral compartment, respectively.
doi:10.1371/journal.pone.0042100.g004
Table 1. Kinetic parameters.
Parameters IFNGFPa IFNGFPApoa
kNUNC (h
21) 1.60 (0.0049)
kINT (h
21) 0.112 (13.21)
kS1 (gene expression* h
21*gene expression21) 1080 (15.93)
kDEG (h
21) 2.12 (1.24)
kS2 (gene expression* h
21*gene expression21) 2.96 (16.32)
kS (pg* h
21*gene expression21) 769 (0.4) 53600 (1.57)
kD (h
21) 22.4 (2.35) 0.0773 (8.02)
kTRAN (h
21) 1.45 (0.86) 0.266 (2.75)
kls (h
21) 120 (11.75) 1720 (17.03)
ksl (h
21) 0.406 (11.85) 0.420 (9.81)
ksp (h
21) NA 1.54 (6.95)
kps (h
21) NA 0.00994 (0.5)
ksb (h
21) 1.0861026 (40.00) 3.7561025 (19.47)
kb0 (h
21) 0.118 (23.22) 0.509 (39.10)
NA: non applicable.
aParameter estimates are listed together with the corresponding coefficient of variation [CV(%)] calculated as the ratio between the standard error and the estimate of
the parameter.
doi:10.1371/journal.pone.0042100.t001
Mathematical Modelling of New Proteins
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e42100
Figure 5. Mean concentration-time profiles of Interferon Stimulated Genes (ISGs) in brain and liver. Mean concentration-time profiles of
Interferon Stimulated Genes (ISGs) in brain and liver. Observed (points) and predicted (lines) levels were plotted versus time for (A–B) mRNA
expression of OAS or ISG15 interferon stimulated genes respectively in liver or (C–D) in brain. ISGs are expressed in gene expression units in log scale.
doi:10.1371/journal.pone.0042100.g005
Table 2. Dynamic parameters.
Genes Parameter LIVER BRAIN
IFNGFPa IFNGFPApoa IFNGFPa IFNGFPApoa
ISG15 kS_ISG (gene expression*h
21)b 491 (7.31) 2.0561023
(21.12)
6.0861024
(17.11)
kD_ISG (h
21) 491 (7.31) 0.127 (24.33)
IFN50_ISG15 (pg*mL
21) 151 (0.47) NA NA
OAS kS_OAS (gene expression*h
21) b 0.0366 (81.69) 7.3761025 (23.47) 2.4561025 (23.47)
kD_OAS(h
21) 1.18 (87.29) 0.101 (23.76)
IFN50_OAS (pg*mL
21) 255 (43.14) NA NA
aParameter estimates are listed together with the corresponding coefficient of variation [CV(%)] calculated as the ratio between the standard error and the estimate of
the parameter.
bBrain parameter units in gene expression*mL*pg21*h21.
doi:10.1371/journal.pone.0042100.t002
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significantly greater IFNGFPApo estimated expression efficiency
(kS) (Table 1), despite the equivalent mRNA and DNA kinetics
and the similar liver concentrations of both compounds.
IFNGFPApo and IFNGFP fusion proteins also showed differ-
ences in the serum level transport driven by the presence of
ApoAI; while the former was only detected at the lipoprotein
depleted plasma, IFNGFPApo was able to travel and distribute
bound to HDLs, and therefore, was mostly detected on the HDL
lipoprotein fraction. This differential serum transport translated
into different distribution features, supported by the need of a
peripheral serum compartment to describe satisfactorily IFNGF-
PApo kinetics (Fig. S1B).
As discussed earlier, when bound to ApoAI, IFNa is able to
incorporate into HDLs, molecules responsible for the transport of
cholesterol from different body tissues to the liver in a process
mediated by the scavenger receptor BI (SR-BI), the main receptors
of ApoAI [35,36]. Considering this prior biological knowledge, an
increased liver distribution and a prolonged half-life driven by
HDLs protection was initially expected after fusion between IFNa
and ApoAI. Given the nature of the molecules (proteins of high
molecular weight) significant differences in mechanisms of
degradation were not expected, and considering that ApoAI is
the only difference between both constructions, parameter
differences are more likely to be explained by biological
impediments to IFNGFPApo elimination or/and greater tissue
distribution due to the inclusion of the ApoAI protein in the
structure. These experimental hypotheses were supported from a
modelling perspective by the lower elimination constant rate
(0.0773 versus 24.4 h21 for IFNGFP and IFNGFPApo, respec-
tively). However, liver vectorization could not be proven, probably
due to the nature of the hydrodynamic technique used for the in
vivo experiments, since hepatic protein levels contained informa-
tion from two main processes; protein expression, and drug
disposition. These results pointed towards a plausible drug
protection, also supported by a previous study where inclusion
of ApoAI into liposomes resulted in hepatic vectorization [15].
Information gathered under different experimental conditions,
such as after intravenous administration of both proteins, different
amounts of DNA injected or sequential administrations would
improve the validity and predictive capacity of the model and
would help to confirm these hypotheses.
Another controversial point to address was brain distribution.
IFNa is believed to cross BBB at low levels (less than 0.2%)
through passive diffusion [37], whereas IA could follow an active
transport mediated by ApoAI presence. Although active transport
could not be proven for the IFNGFPApo molecule, a three times
higher brain diffusion rate was found for the higher molecular
weight compound (IFNGFPApo), suggesting the existence of a
facilitated transport that would be mediated by ApoAI, the only
difference between both compounds. Similar results were found
when ApoAI [19] or other molecules with known receptors at
brain level were used to increase transport of therapeutic
molecules across the BBB [18,38].
Regarding the efficacy of the two drugs, interferons are known
to induce the expression of multiple genes implied not only in
antiviral activities, but also in the lipid metabolism or apoptosis.
Interferon-stimulated genes ISG15 and OAS were selected to
evaluate the treatment effectiveness for their higher response to
interferon [37,39]. Despite the different kinetic profiles exhibited
by IFNGFPApo and IFNGFP at the three analysed levels, a
common dynamic model for each ISG could successfully describe
the gene expression induced by IFNa in liver after either plasmid
administration, suggesting that modifications introduced by ApoAI
fusion did not alter its biological activity at this level. Contrary to
liver, brain ISGs dynamics could not be fitted with a common
model, and different synthesis rates for each gene and molecule
were estimated (Table 2), IFNGFP being more efficient than
IFNGFPApo. Interestingly, brain IFNGFP exit was also lower,
suggesting an increased brain distribution that could also explain
the apparent different gene expression efficiencies at this level.
New experiments where IFNGFP and IFNGFPApo are quantified
in different brain areas would be desirable to understand the
system better.
In conclusion, incorporation of exogenous compounds, such as
GFP, has facilitated the determination of the time-profiles of IFN
and IA in three main organs: blood, liver and brain, and the
development of an integrated kinetic/dynamic model. Different
kinetic properties were concluded for the two compounds,
estimating a prolonged half-life and distribution properties.
Regardless kinetic differences, each of the gene profiles was
successfully described by the same set of parameters for both
molecules, indicating a preservation of the native IFNa activity in
the target organ, although not in the brain, where more
information would be needed before drawing any conclusion.
Ourmodelaimstomathematicallydescribethedifferentbiological
processes that take place in the body after plasmid administration
(mRNA transcription, protein synthesis, distribution and so on) in a
simplifiedway.Henceit isexpectedthat this samemodelstructurecan
help to describe the behaviour of other drugs, though with different
sets of parameters, that account for their specific pharmacokinetic
and pharmacodynamics characteristics. As an example, the tran-
scriptionmodelapplied toourdatawasusedpreviously to successfully
describe the luciferase activity [28].
Multiple time data analysis provides a greater amount of
information, but also complicates global data interpretation. The
modelling approach incorporated in the current study allows us to
design experiments and to integrate all available information and
hence permits us to estimate parameters with a certain biological
relevance. Clearly, the integration of information has allowed us to
scrutinize kinetic and dynamic differences between the two
compounds and to support them from a biological point of view,
but also to identify processes that are not well understood and to
propose new model-driven experiments to better understand the
system.
Materials and Methods
Ethics Statement
We certify that mice were treated in accordance with the
guidelines of the University of Navarra (UNAV, Pamplona,
Spain).
Cell Lines and Animals
Cell lines. 293T cell line derived from human kidney and
L929 mouse fibroblast cell line were obtained from American
Type Culture Collection, LGC Promochem (Molsheim, France).
Both cell lines were cultured in DMEM (Gibco) supplemented
with 10% FCS, 100 U/mL streptomycin, 100 mg/mL penicillin
and 1% L-glutamine at 37uC and 5% of CO2.
Animal handling. Animal experiments were performed on 8-
week-old female immunocompetent BALB/c mice (Harlan,
Barcelona, Spain). Plasmid administration was performed by
hydrodynamic injection as previously described [33]. Briefly,
plasmids (20 mg of plasmid per mouse) were resuspended in
1.8 mL of saline solution and administered through the tail vein
over a short period of time to achieve efficient gene transfer
and expression in the liver. Blood samples were collected from
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retro-orbital plexus, after isofluorane (Abbott, Chicago, IL, USA)
anaesthesia.
Cloning of GFPApo, IFNGFP and IFNGFPApo Plasmids
eGFP plasmid (peGFP) was kindly donated by Dr. Hernandez-
Alcoceba. IFNa plasmid (pIFN), ApoAI plasmid (pApoAI) and
IFNa bound to ApoAI plasmid (pIFNApoAI) had been previously
synthesized in the laboratory [13].
Three different sequences of eGFP were designed for each of
the vectors proposed: GFP fused to ApoAI (pGFPApoAI), GFP
fused to IFNa (pIFNGFP) and GFP in between IFNa and ApoAI
(pIFNGFPApo). PCR amplifications were carried out with the
selected primers (listed Table S1). The resulting products were
purified (Qiagen, Madrid, Spain), cloned into pcDNATM3.1/V5-
His TOPOH TA expression vectors, according to the instructions
provided by the manufacturer, and transformed into Top10
bacteria (Invitrogen, CA, USA) for amplification. To proceed with
the fusion of eGFP sequences to their vectors (pApo, pIFN and
pIA respectively), both plasmids were digested with the appropri-
ate enzymes (New England Biolabs, UK) for each case.
Afterwards, the open plasmids and their purified inserts were
fused using T4 DNA ligase High Concentration and 2X Rapid
Ligation Buffer (Promega, Madison, WI, USA). New plasmids
were kept at 220uC until their use.
pGFPApo. sense primer FwspGFP, introducing a signal
peptide, and antisense primer RvAscIGFP, introducing the
restriction site for the AscI enzyme (GGCGCGCCC) in 39 end
of eGFP were designed and used as templates for eGFP
amplification. peGFP and pApoAI were digested independently
with AscI and BstBI enzymes and cloned as previously described.
pIFNGFP. sense primer FwAscIGFP, introducing the restric-
tion site for the AscI enzyme (GGCGCGCCC) in 59 end of eGFP,
and antisense primer RvTaaGFP, were designed and used as
templates for eGFP amplification. peGFP and pIFN were digested
independently with AscI and BstBI enzymes and cloned as
previously described.
pIFNGFPApo. sense primer FwAscIGFP and the antisense
primer RvAscIGFP previously discussed, were designed and used
as templates for eGFP amplification. peGFP and pIFNApo were
digested independently with AscI enzyme and cloned as previously
described.
Evaluation of pGFPApo, pIFNGFP and pIFNGFPApo
Fluorescence and confocal microscopy. GFP fluorescence
was evaluated through fluorescence microscopy (Leica Micro-
systems, Germany). Briefly, 26105 293T cells per well were seeded
in 6-well-plates (CellstarH, Greiner bio-one, Germany). When 80%
confluence was achieved, cells were transfected with one of the
three plasmids in presence of PEI 25000 kDa (PolyScience, IL,
USA). Fluorescence was directly analysed 24 h after transfection.
To study protein location inside the cell, 24 hours after
transfection with pGFPApo, pIFNGFP or pIFNGFPApo cells
were rinsed and incubated in presence of BODIPY TR 5 mM
(Invitrogen, Carlsbad, CA, USA) 30 min at 4 uC. Subsequently,
cells were rinsed with cold cell medium and incubated for another
30 min before confocal microscopy analysis. Volocity software was
used to evaluate GFP and BODIPY colocalization.
Determination of IFNa Activity
26105 293T cells per well were seeded in 6-well-plates
(CellstarH, Greiner bio-one, Germany) and cells were transfected
as previously described. After 24 h, supernatant containing the
proteins expressed by the cells was collected to determine the
capacity of serial dilutions of supernatants to protect L929
fibroblast cells against the encephalomyocarditis virus following
the protocol detailed in [13].
Detection of IFNa and ApoAI in the Lipoprotein Fractions
of Plasma
24 hours after hydrodynamic administration of the pApoAI,
pIFNGFP and pIFNGFPApo plasmids, blood samples were taken
and very low density lipoprotein (VLDL), low density lipoprotein
(LDL), high density lipoprotein (HDL) and lipoprotein depleted
plasma (LDP) fractions were isolated from pool plasma samples by
floating after sequential differential ultracentrifugations in sodium
bromide gradient [40].
Levels of IFNa in each of the fractions were measured by
ELISA in NUNCTM maxisorp 96-wells plates (Bioreba, Germany).
RAMMA-1 (PBL) was used as anti-mIFNa antibody and HRP-
conjugated donkey a-rabbit IgG (Southern Biotechnology, Bir-
mingham, AL, USA) as secondary antibody. Absorbance was read
at 450 nm and corrected 540 nm.
Detection of ApoAI was performed by Western Blotting
analysis. Lipoprotein fractions were separated by SDS-PAGE
(10%) and transferred to a nitrocellulose membrane (Whatman,
Maidstone, UK). Goat monoclonal antibody against mApoAI
(Santa Cruz Biotechnology,CA, USA) and HRP- conjugated anti-
goat IgG were used to detect ApoAI presence and ECL Plus
Western Blotting Detection Reagent (Amersham, Barcelona,
Spain) was used to reveal the membrane.
Sampling Collection and Determination
To study the evolution over time of IFNGFP and IFNGFPApo
in three main compartments: blood, brain and liver, plasmids were
administered to mice as previously described. At 6, 9, 13, 24 and
48 hour time points, blood samples were collected and animals
were sacrificed (n = 6–8 mice per point and group obtained from
two independent studies). In a third independent study, blood
samples at earlier times (1, 3 and 7 hours) were obtained (n = 3
mice per group).
Blood samples were centrifuged 5 min at 9100xg twice and
serums were kept at 220uC until their use. Half of each organ was
homogenized in distilled water supplemented with a cocktail of
protease inhibitors (CompleteH EDTA-free, Roche, Barcelona,
Spain) and centrifuged to separate proteins from tissue. Superna-
tants were kept at 280uC until their use. The other half was
conserved for RNA extraction.
GFP protein in serum, liver and brain was quantified by GFP
ELISA Kit (Cell Biolabs, Inc. Ca, USA) following manufacturer’s
instructions.
GFP levels in liver and brain were normalized using the total
protein content in the organ, calculated by Bradford analysis.
Normalization between experiments was also performed to
account for the inter-experiment variability.
29-59 OAS, and ISG15 interferon stimulated genes (ISGs) were
determined as a measure of IFN activity. mIFNa mRNA was also
measured as an indicator of plasmid expression. In order to
perform the dynamic analysis, total RNA from mice livers and
brains was isolated using TRI reagent (Sigma, Dorset, UK). The
concentration and purity of samples were determined by
absorbance at 260 and 280 nm, with background correction at
320 nm in a spectrophotometer. RNA was treated with DNase I
and retrotranscribed to cDNA with MMLV RT in the presence of
RNase OUT (all the reagents from Invitrogen, Carlsbad, CA,
USA). The reaction was incubated for 1 hour at 37uC, denatured
for 1 minute at 95uC and taken to 4uC. The samples were used
immediately for qPCR or stored at 220uC.
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Primers for quantitative real time RT-PCR are listed in Table
S1. Murine actin was used to standardize gene expression, given
that its mRNA levels remained constant with all treatments at
several time points (data not shown). The mRNA values were
represented by the formula 2DCt, where DCt indicates the
difference in the threshold cycle between mActin and the target
genes (all reagents from BioRad, Hercules, CA, USA).
Data Analysis
The following main processes after administration of plasmids
by hydrodynamic injection were described based on a semi-
mechanistic computational model using ordinary differential
equations (see sets of equations 1–12): (i) hepatic transcription
from pDNA to mRNA, (ii) translation of mRNA to proteins in the
liver and kinetics of proteins to serum, (iii) protein brain
distribution, and (iv) dynamics of protein induced gene expression
in liver and brain.
Expression levels of mRNA, GFP levels of protein measured in
liver, serum and brain, and interferon stimulated genes in brain
and in liver of both molecules (IFNGFP and IFNGFPApo) were
used to develop the model. The model was developed sequentially
in different steps (see below), and at each step all data available
were fitted simultaneously. During the analysis, data were
logarithmically transformed. For each measured response, the
discrepancy (ej) between an observation obtained at time j
th (Yobs,j)
and the corresponding prediction from the model (YPRED,j) was
accounted for as follows: Yobs,j = Ypred,j x (1+ej). The set of es
forms a random variable with mean 0 and variance equal to v2,
which is also estimated as another (random) parameter in the
model.
The software NONMEM VI [41] was used during the
mathematical analyses. Selection between different model candi-
dates and performance of the selected models was made on the
basis of different criteria: (i) precision of parameter estimates, (ii)
the minimum value of the objective function value provided by
NONMEM (MVOF) and approximately equal to 22xlog
(likelihood) (-2LL) and (iii) agreement between observations and
model predictions. Differences between two hierarchical (nested)
models were compared with a x2 distribution in which a decrease
in the MVOF (dMVOF) of 3.84, 6.63 or 10.83 points was
considered significant at the 5%, 1% or 0.1% level respectively, for
one extra model parameter [41]. Non nested models were
compared using the Akaike information criteria (AIC) calculated
as Nxlog(RSS/n)+2xNp, where N is the number of data points,
RSS the residual sum of squares and Np is the number of
parameters in the model [42]. The models with the lowest value of
AIC, given that precision of model parameters and data
description was adequate, were finally selected.
Exploratory analysis of the data and model evaluation graphs
was performed with Prism 5 (GraphPad Software, Inc) and R (R-
project).
Model Building
Figure 4 represents schematically the integrated model finally
selected to describe all data available in the current study. In the
following, the main modelling assumptions and a detailed
mathematical representation of the final model is provided.
(i) Hepatic transcription from pDNA to mRNA. After
plasmid administration by hydrodynamic injection, almost all the
plasmid is located into the liver, where it is expressed [33]. For
modelling purposes, it was assumed that drug (plasmid) was
directly administered into the liver.
Kinetics of mRNA was modelled simultaneously for both
molecules, fitting a model previously developed by Berraondo et al
[28] where different degrees of active DNA (DNA and DNA’),
both able to induced mRNA synthesis, although with different
transcription rate constants (kS1 and kS2 respectively), coexisted in
the nucleus after pDNA internalisation. Equations 1–3 represent
the model for the dynamics of hepatic transcription from pDNA to
mRNA.
dDNA
dt
~-(kNUNCzkINT)|DNA ð1Þ
dDNA0
dt
~kINT|DNA-kINT|DNA
0 ð2Þ
dmRNA
dt
~kS1|DNAzkS2|DNA
0-kDEG|mRNA ð3Þ
Since information about the effective amount of pDNA
reaching the liver was not available, an arbitrary value of 1 was
assumed. The amounts of DNA, DNA’, and mRNA at the
moment of the pDNA injection (initial conditions) were 1, 0, and
0, respectively. kNUNC and kDEG are the first order elimination rate
constants of DNA and mRNA respectively, kINT is the first order
rate constant of conversion and degradation of DNA’, and kS1 and
kS2, first order rate constants of expression of mRNA from DNA
and DNA’, respectively.
(ii) Translation of mRNA to proteins in the liver and
kinetics of proteins to serum. To account for the levels of
proteins in the liver, as a result of hepatic protein expression, and
their release to systemic circulation, parameters kNUNC, kDEG,
kINT, kS1 and kS2 were fixed to those obtained in the previous step.
Liver and brain protein density was considered to be 1 mg/mL,
and volume of distribution was assumed to be 1 mL for both
molecules.
A simultaneous fit was initially attempted for both proteins.
However, different dynamics were observed, and therefore,
independent models were developed for IFNGFP and IFNGF-
PApo. The set of ordinary differential equations represented by
expressions 4 to 7 were used to describe the time courses of
IFNGFP levels in liver and serum (lIFNGFP, and sIFNGFP,
respectively), where kS and kD are the hepatic first order rate
constants of synthesis and degradation of the protein, respectively
and kTRAN represents the first order constant rate of transit
accounting for the delay in the synthesis of liver protein from
mRNA;. The parameters kls, ksl and ksb represent the rate
constants of distribution between the liver (l) and serum (s), and
serum and brain (br) compartments.
dTRAN1
dt
~kTRAN|mRNA-kTRAN|TRAN1 ð4Þ
dTRANn
dt
~kTRAN|TRANn-1-kTRAN|TRANn ð5Þ
dlIFNGFP
dt
~kS|mRNA-(kDzkls)|lIFNGFPzksl
|sIFNGFP
ð6Þ
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dsIFNGFP
dt
~kls|lIFNGFP-(kslzksbr)|sIFNGFP ð7Þ
In the case of IFNGFPApo protein, apart from the transit
compartments described by eq 4 and 5, a peripheral distribution
compartment (p) was required to describe the kinetics of the
protein in serum.
dlIFNGFPApo
dt
~kS|TRANn-(kDzkls)
|lIFNGFPApozksl|sIFNGFPApo
ð8Þ
dsIFNGFPApo
dt
~kls|lIFNGFPApo-(kslzkspzksbr)
|sIFNGFPApozksp|pIFNGFPApo
ð9Þ
dpIFNGFPApo
dt
~ksp|sIFNGFPApo-kps
|pIFNGFPApo
ð10Þ
where kls, ksl, ksb, kS and kD represent the same processes as for
IFNGFP case, but with different values. ksp and kps correspond to
the distribution rate constants between central serum compart-
ment and peripheral compartment.
(iii) Protein brain distribution. Brain levels of proteins
(brIFN standing for brIFNGFP or brIFNGFPApo) were described
using a model in which input from the serum and disappearance
from the brain compartments were described through a first order
rate process represented by the rate constants ksbr and kE,
respectively. In equation 11, the model corresponding to
brIFNGFP and brIFNGFPApo is shown.
dbrIFN
dt
~ksbr|sIFN-kE|brIFN ð11Þ
During the analysis of the brain protein levels, the predicted
time profiles of both proteins in serum obtained from the previous
sub-models (equations 1–10) were used.
(iv) Dynamics of protein induced gene expression in liver
and brain. The profiles of the brain and liver levels (brISGs and
hISGs, respectively) of the following ISGs, OAS and ISG15, were
described using a model that assumes that (i) the ISGs synthesis is
mediated by the (model predicted) levels of the corresponding
proteins in liver or brain, and (ii) ISGs degradation occurs through
a first order process (see equation 12), where parameters kS_ISG
and kD_ISG represents the first order process of synthesis and
degradation, respectively.
dISG
dt
~kS ISG|IFN-kD ISG|ISG ð12Þ
Kinetic and dynamic processes (i.e., synthesis, degradation,
distribution) are represented in equations 1–12 as linear processes;
however, during model building non-linear models were also
explored and tested for model improvements.
Supporting Information
Figure S1 Comparison of model performances. Model
predictions against IFNGFPApo observation (points) when no
transit compartments (dashed line), or transit compartments with
(solid lines) or without peripheral serum distribution (dotted line)
are evaluated in liver (A) or serum (B).
(TIF)
Figure S2 Mean liver model predictions for IFNGFP
(solid line) and IFNGFPApo (dashed line) compounds.
Protein levels are expressed in pg/mL.
(TIF)
Figure S3 Dynamic of mRNA (gene expression units),
liver transit compartments (arbitrary units) and hepatic
IFNGFP (left panel) or IFNGFPApo levels (right panel)
(pg/mg protein).
(TIF)
Table S1 List of primers used for PCR and qRT-PCR.
(DOC)
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